Abstract
Despite being widely practised there is little or no evidence to support the use of antifungal prophylaxis in febrile nuetropenic patients. With the greater recognition of risk factor, the incereasing readiness to use imaging techniques such as the high-resolution CT scan and new methods for detecting fungi such as Aspergillus galactomannan on the one hand and the widening choice of drugs on the other hand, it may be possible to move away from prophylaxis towards pre-emptive treatment when the prevalence of fungal disease is low. Howeveer, the case still has to be proven convincingly by conducting formal clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
